Dorzox T Eye Drops (Dorzolamide Hydrochloride) are topical carbonic anhydrase inhibitor eye drops formulated to reduce elevated intraocular pressure (IOP). By inhibiting the carbonic anhydrase enzyme in the ciliary body, Dorzolamide decreases aqueous humor production, resulting in a significant reduction in IOP.

These drops are indicated for the treatment of open-angle glaucoma and ocular hypertension, either as monotherapy or in combination with other IOP-lowering agents such as beta-blockers (e.g., timolol). By lowering IOP, Dorzox T helps slow optic nerve damage and preserve visual function in glaucoma patients. Available through trusted online pharmacy platforms, it offers a reliable and effective option for long-term ocular care.

• Long-term management of elevated IOP in open-angle glaucoma and ocular hypertension.
• Effective when prostaglandin analogs or beta-blockers are insufficient or not tolerated.
• Can be combined with other therapies for enhanced IOP control.

• Reduces IOP by suppressing aqueous humor formation.
• Can be used as initial therapy or adjunctive treatment.
• Effective in combination regimens for better IOP control.
• Local ocular action minimizes systemic side effects.

• Adults: Instill one drop in the affected eye(s) three times daily.
• Pediatrics (≥2 years): Same as adults; short-term studies (up to 3 months) support safety and efficacy.
• Allow at least 5 minutes between different eye medications.
• Remove contact lenses before application; reinsert after 15 minutes.
• Shake gently if directed before use.

• Store at 15–25°C, protected from light.
• Keep the bottle tightly closed to avoid contamination.

• Common: Ocular burning, stinging, blurred vision, bitter taste, mild eye discomfort.
• Less common: Conjunctivitis, eyelid inflammation, corneal edema.
• Rare: Allergic reactions, systemic effects in patients with severe renal impairment.